Xie Rui et al. investigated the combinational treatment between the two by using TRAIL-resistant GC cell lines, and the study demonstrated that TRAIL+LIQ could significantly inhibit gastric cancer progression by suppressing cellular proliferation, migration, and tumor growth in vivo by regulating ROS and JNK activation [62]. Here, TNFSF10 is linked to gastric cancer.